DnaJ heat shock protein family (Hsp40) member C12Genealiases: HPANBH4 · JDP1
Q-omics provides the consensus-scored DNAJC12 profile across patient tissues and cancer cell-line models. DNAJC12 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, DNAJC12 is differentially expressed in 11, with the highest sampling consensus in LUAD. Additionally, DNAJC12 protein abundance shows 26,096 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, LUAD, and GBM as cancer lineages where DNAJC12 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DNAJC12 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DNAJC12 survival associations across molecular data types. DNAJC12 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (2) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DNAJC12 RNA expression–survival associations across cancer types. High DNAJC12 expression shows unfavorable associations in KIRC, UVM, STAD and HNSC, but favorable associations in BRCA and LGG. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for DNAJC12 RNA expression.
This table summarizes DNAJC12 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 5. The strongest signals are observed in LUAD for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for DNAJC12. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DNAJC12 shows lower tumor expression in KICH, LIHC, UCEC and KIRC and higher tumor expression in LUAD and BRCA. The LUAD box plot shows higher DNAJC12 RNA expression in tumor versus normal tissue (log2 FC = +2.740, t-test p < 0.001).
This table shows molecular features associated with DNAJC12 in patient tissues and cancer cell lines. In patient samples, DNAJC12 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, DNAJC12 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in BONE and SKIN.
